Anna M Wu

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Antibodies for molecular imaging of cancer
    Anna M Wu
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Cancer J 14:191-7. 2008
  2. ncbi request reprint Arming antibodies: prospects and challenges for immunoconjugates
    Anna M Wu
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Box 951770, 700 Westwood Plaza, Los Angeles, California 90095, USA
    Nat Biotechnol 23:1137-46. 2005
  3. pmc Blockade of epithelial membrane protein 2 (EMP2) abrogates infection of Chlamydia muridarum murine genital infection model
    Kaori Shimazaki
    Molecular Biology Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    FEMS Immunol Med Microbiol 55:240-9. 2009
  4. pmc Engineered antibodies for molecular imaging of cancer
    Anna M Wu
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA Electronic address
    Methods 65:139-47. 2014
  5. doi request reprint Antibodies and antimatter: the resurgence of immuno-PET
    Anna M Wu
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1770, USA
    J Nucl Med 50:2-5. 2009
  6. pmc Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors
    Jeffrey V Leyton
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 14:7488-96. 2008
  7. pmc Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California at Los Angeles, 90095, USA
    Cancer Res 65:5907-16. 2005
  8. pmc Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins
    Vania E Kenanova
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, California NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, CA 90095 1770, USA
    Protein Eng Des Sel 23:789-98. 2010
  9. pmc Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors
    Jeffrey V Leyton
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 22:209-16. 2009
  10. ncbi request reprint Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging
    Katy M Venisnik
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 9:267-77. 2007

Research Grants

Collaborators

Detail Information

Publications77

  1. doi request reprint Antibodies for molecular imaging of cancer
    Anna M Wu
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Cancer J 14:191-7. 2008
    ..Antibody imaging can provide a sensitive, noninvasive means for molecular characterization of cell surface phenotype in vivo, which can in turn guide diagnosis, prognosis, therapy selection, and monitoring of treatment in cancer...
  2. ncbi request reprint Arming antibodies: prospects and challenges for immunoconjugates
    Anna M Wu
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Box 951770, 700 Westwood Plaza, Los Angeles, California 90095, USA
    Nat Biotechnol 23:1137-46. 2005
    ..Nonetheless, highly promising results from preclinical models will continue to drive the clinical development of this therapeutic class...
  3. pmc Blockade of epithelial membrane protein 2 (EMP2) abrogates infection of Chlamydia muridarum murine genital infection model
    Kaori Shimazaki
    Molecular Biology Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    FEMS Immunol Med Microbiol 55:240-9. 2009
    ..These findings support EMP2 as a potential preventative and therapeutic target for genital chlamydial infection...
  4. pmc Engineered antibodies for molecular imaging of cancer
    Anna M Wu
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA Electronic address
    Methods 65:139-47. 2014
    ....
  5. doi request reprint Antibodies and antimatter: the resurgence of immuno-PET
    Anna M Wu
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1770, USA
    J Nucl Med 50:2-5. 2009
    ..Convergence of knowledge regarding key biomarkers that define normal biologic processes and disease with protein and imaging technology makes this an opportune time to revisit the combination of antibodies and PET, or immuno-PET...
  6. pmc Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors
    Jeffrey V Leyton
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 14:7488-96. 2008
    ..In this study, the 2B3 minibody (an 80-kDa engineered antibody fragment) has been produced for rapid targeting and imaging...
  7. pmc Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California at Los Angeles, 90095, USA
    Cancer Res 65:5907-16. 2005
    ..1 +/- 1.5% ID/g). Thus, by manipulating the size and format of anti-p185(HER2) antibody fragments, the kidney activity was reduced and high or low expression of p185HER2 in xenografts could be distinguished by microPET imaging...
  8. pmc Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins
    Vania E Kenanova
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, California NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, CA 90095 1770, USA
    Protein Eng Des Sel 23:789-98. 2010
    ..H464 appears to be most crucial for FcRn binding (greatest reduction in MRT), followed by H510 and H535. By mutating the DIII scaffold, we can dial serum kinetics for imaging or therapy applications...
  9. pmc Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors
    Jeffrey V Leyton
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 22:209-16. 2009
    ..Although the higher affinity bm2B3-Db8 demonstrated improved tumor retention at later time points (20 h), it did not improve tumor targeting or imaging compared with p2B3-Db8 at 12 h...
  10. ncbi request reprint Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging
    Katy M Venisnik
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 9:267-77. 2007
    ..4% ID/g) at 21 hours. Although further optimization of this fusion protein may be needed to improve in vivo performance, the diabody-GLDelta15 is a promising optical imaging probe for tumor detection in vivo...
  11. pmc Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines
    Kaori Shimazaki
    Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Clin Cancer Res 14:7367-77. 2008
    ..The present study assesses the suitability of EMP2 as a therapeutic target...
  12. doi request reprint Engineered antibody fragments with infinite affinity as reporter genes for PET imaging
    Liu H Wei
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Nucl Med 49:1828-35. 2008
    ..The objective of the present study was to evaluate a new approach for reporter gene imaging based on cell surface expression of antibody fragments that can irreversibly bind to radiometal chelates...
  13. pmc An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors
    Eric J Lepin
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 37:1529-38. 2010
    ..However, the humanization and antibody fragment reformatting decreased its apparent affinity. Here, we sought to evaluate PET imaging contrast with affinity matured minibodies...
  14. doi request reprint Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer
    Mark D Girgis
    Department of Surgery, UCLA, Los Angeles, California 90095, USA
    J Surg Res 170:169-78. 2011
    ..Our goal was to develop and characterize the anti-CA19-9 diabody fragment and determine its ability to provide antigen specific imaging of pancreas cancer...
  15. pmc Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095
    Protein Eng Des Sel 17:21-7. 2004
    ..This format will provide a versatile platform for targeting a variety of agents to CEA-positive tumors...
  16. pmc Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody
    Scott M Knowles
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California
    J Nucl Med 55:452-9. 2014
    ..In this study, we sought to develop immunoPET agents using (124)I- and (89)Zr-labeled anti-PSCA A11 minibodies (scFv-CH3 dimer, 80 kDa) and evaluate their use for quantitative immunoPET imaging of prostate cancer...
  17. pmc Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments
    Maoyong Fu
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 15:68-78. 2013
    ....
  18. pmc Positive progress in immunoPET--not just a coincidence
    Katelyn E McCabe
    David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Cancer Biother Radiopharm 25:253-61. 2010
    ..Antibody-based PET probes constitute a valuable class of molecular imaging agents, and the progress made preclinically should expedite the transition of these targeted diagnostics to clinical applications...
  19. pmc ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, UCLA Crump Institute for Molecular Imaging, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 23:243-9. 2010
    ..Specific tumor targeting and high contrast images were achieved with the anti-CD20 diabodies. These agents extend the repertoire of reagents that can potentially be used to improve detection of low-grade lymphomas...
  20. ncbi request reprint A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments
    Gregory Z Ferl
    Department of Computer Science, University of California, Los Angeles, USA
    Mol Cancer Ther 5:1550-8. 2006
    ..In addition, elimination of a small amount of mAb in the kidneys is shown to be required for a successful fit of model to data...
  21. ncbi request reprint Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA
    J Immunother 30:396-405. 2007
    ..These data support further development of hu1G8 anti-PSCA antibody for targeted imaging and therapy for tumors of urogenital origin...
  22. ncbi request reprint Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 700 Westwood Plaza, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 17:315-23. 2004
    ..62 h) was similar. Thus, minibodies with different specificities display similar pharmacokinetics, while tumor uptake may vary depending on the antigen-antibody system...
  23. pmc Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo
    Richard Tavare
    Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Howard Hughes Medical Institute, Department of Microbiology, Immunology, and Molecular Genetics, and Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095
    Proc Natl Acad Sci U S A 111:1108-13. 2014
    ..Both (64)Cu-radiolabeled Mbs produced high-contrast immuno-PET images 4 h postinjection and showed specific uptake in the spleen and lymph nodes of antigen-positive mice. ..
  24. doi request reprint An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles
    Mark D Girgis
    Department of Surgery, Veterans Healthcare Affairs, Greater Los Angeles, Los Angeles, California Department of Surgery, UCLA, Los Angeles, California
    J Surg Res 185:45-55. 2013
    ..The goal of this study was to engineer an anti-carbohydrate antigen 19-9 (CA19-9) cys-diabody fragment in hopes of targeting nanoparticles to pancreatic cancer...
  25. pmc Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2
    Shannon J Sirk
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Bioconjug Chem 19:2527-34. 2008
    ..Conjugates retained both specificity and fluorescence, demonstrating the successful expansion of the CysDb repertoire to new targets and to new site-specific conjugation possibilities...
  26. pmc Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging
    Bhaswati Barat
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1770, USA
    Mol Imaging Biol 13:526-35. 2011
    ..The objective of this article is to develop internalizing positron emission tomography (PET) reporter genes for tracking genetically modified T cells in vivo...
  27. pmc Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection
    Bhaswati Barat
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Bioconjug Chem 20:1474-81. 2009
    ....
  28. pmc A differential cell capture assay for evaluating antibody interactions with cell surface targets
    David J Sherman
    Department of Molecular and Medical Pharmacology, Crump Institute of Molecular Imaging, California NanoSystems Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Anal Biochem 401:173-81. 2010
    ..This approach can find utility when an antibody or antibody fragment against a known cell line needs to be selected for targeting studies...
  29. ncbi request reprint Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors
    Katy M Venisnik
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 19:453-60. 2006
    ....
  30. pmc An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors
    Katelyn E McCabe
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA
    Mol Imaging Biol 14:336-47. 2012
    ..The purpose of this study was to generate and evaluate a positron emission tomography (PET) radiotracer targeting activated leukocyte cell adhesion molecule (ALCAM)...
  31. pmc Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging
    Vania Kenanova
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, 700 Westwood Plaza, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 36:104-14. 2009
    ..We have developed a reporter gene based on carcinoembryonic antigen (CEA), a human protein with limited normal tissue expression...
  32. ncbi request reprint Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, 700 Westwood Plaza, Los Angeles, California 90095, USA
    Nat Protoc 1:2048-60. 2006
    ..The time frame for completing the procedure is about 6 months, provided that no complications are encountered...
  33. pmc Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Nucl Med 50:1500-8. 2009
    ..To provide more sensitive, tumor-specific PET imaging of NHL, we sought to develop PET agents targeting CD20...
  34. pmc A fully human scFv phage display library for rapid antibody fragment reformatting
    Keyu Li
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 570 Westwood Plaza, Box 951770, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 28:307-16. 2015
    ....
  35. pmc Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies
    Richard Tavare
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
    J Nucl Med 56:1258-64. 2015
    ..5 and 2.43, respectively, for (89)Zr-immuno-PET detection of helper and cytotoxic T cell populations...
  36. pmc Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer
    Scott M Knowles
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California
    Clin Cancer Res 20:6367-78. 2014
    ..We compare A11 minibody immunoPET to (18)F-Fluoride PET bone scans for detecting prostate cancer bone tumors and evaluate the ability of the A11 minibody to image tumor response to androgen deprivation...
  37. pmc Antibody vectors for imaging
    Tove Olafsen
    UCLA Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA
    Semin Nucl Med 40:167-81. 2010
    ..The preclinical data presented are compelling, and it is evident that antibody-based molecular imaging tracers will play an important future role in the diagnosis and management of cancer and other diseases...
  38. pmc Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology
    Scott M Knowles
    David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    J Clin Oncol 30:3884-92. 2012
    ....
  39. ncbi request reprint Tailoring antibodies for radionuclide delivery
    Vania Kenanova
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 700 Westwood Plaza, Los Angeles, CA 90095, USA
    Expert Opin Drug Deliv 3:53-70. 2006
    ..Examples from the literature that represent different approaches to accomplishing this task in terms of their successes as well as limitations, and perspectives for the future are discussed...
  40. pmc An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy
    Richard Tavare
    Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, California Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California
    Cancer Res 76:73-82. 2016
    ....
  41. pmc Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation
    Richard Tavare
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 27:317-24. 2014
    ..Interestingly, the conjugation strategy not only affects tumor targeting but also hepatic and renal uptake/clearance. ..
  42. pmc Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment
    Mark D Girgis
    Department of Surgery, UCLA, 10833 LeConte Ave, Rm 54 140, Los Angeles, CA 90095, USA
    EJNMMI Res 1:24. 2011
    ..Thus, we sought to evaluate the potential of CEA as a pancreatic cancer target utilizing a rapidly clearing engineered anti-CEA scFv-Fc antibody fragment with a mutation in the Fc region [anti-CEA scFv-Fc H310A]...
  43. ncbi request reprint Protein targeting constructs in alpha therapy
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Curr Radiopharm 4:197-213. 2011
    ..e. diabody) and tetramer, CH2 domain deleted antibody fragments); other protein targeting constructs such as affibodies and peptides as well as liposomal delivery...
  44. doi request reprint ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 570 Westwood Plaza, CNSI 4335, Box 951770, Los Angeles, CA 90095 1770, USA
    Tumour Biol 33:669-77. 2012
    ..This approach can be broadly applied to antibodies targeting cell surface biomarkers for molecular imaging of tumors and should be highly translatable for clinical use...
  45. pmc Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments
    Keyu Li
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California
    Mol Cancer Ther 13:2607-17. 2014
    ..In conclusion, these fully human antibody fragments inhibit MET-dependent cancer cells and enable rapid immunoPET imaging to assess MET expression levels, showing potential for both therapeutic and diagnostic applications...
  46. pmc A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts
    Matthew M Rochefort
    Department of Surgery, UCLA, 570 Westwood Plaza, Bldg 114, CNSI, Rm4324E, Los Angeles, CA, 90095, USA
    Mol Imaging Biol 16:721-9. 2014
    ..We sought to develop a Fc-mutated, anti-CA19-9 antibody fragment (anti-CA 19-9 scFv-Fc H310A) to provide micro-positron emission tomography (microPET) imaging of pancreatic cancer xenografts...
  47. pmc Endocytosis and intracellular trafficking properties of transferrin-conjugated block copolypeptide vesicles
    Uh Joo Choe
    Department of Bioengineering, University of California, Los Angeles, 420 Westwood Plaza, 5121 Engineering V, Los Angeles, California 90095, United States
    Biomacromolecules 14:1458-64. 2013
    ..Furthermore, endocytosis and immunostaining experiments confirmed that the Tf conjugated on the vesicle surface plays a critical role in the internalization and subsequent intracellular trafficking behavior of the vesicles...
  48. pmc Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum
    Bhaswati Barat
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Biomol Eng 24:283-91. 2007
    ..Utilization of ER retained biotin ligase for biotinylation of protein is an attractive alternative for efficiently producing uniformly biotinylated recombinant proteins for a variety of avidin-biotin technologies...
  49. ncbi request reprint ImmunoPET Imaging of Murine CD4+ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging
    Amanda C Freise
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Crump Institute for Molecular Imaging, University of California, 570 Westwood Plaza, CNSI, PO Box 951770, Los Angeles, CA, 90095 1770, USA
    Mol Imaging Biol . 2016
    ....
  50. pmc 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice
    Gobalakrishnan Sundaresan
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    J Nucl Med 44:1962-9. 2003
    ..The present work evaluated the minibody or diabody labeled with (124)I, for imaging tumor-bearing mice using a high-resolution small-animal PET system...
  51. pmc Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, California NanoSystems Institute, Los Angeles, California 90095, USA
    J Biol Chem 285:39239-48. 2010
    ..In support of this concept, lung LPL levels were significantly lower in Gpihbp1(-/-) mice than in Gpihbp1(+/+) mice. In addition, Lpl(-/-) mice expressing human LPL exclusively in muscle contained high levels of human LPL in the lung...
  52. pmc CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer
    Mark D Girgis
    Department of Surgery, UCLA, 10833 LeConte Avenue, Rm 54 140, Los Angeles, CA 90095, USA
    Int J Mol Imaging 2011:834515. 2011
    ..Conclusion. We show in vivo targeting of our antigen positive xenograft with a radiolabeled anti-CA19-9 antibody. These data demonstrate the potential to achieve anti-CA19-9 antibody based positron emission tomography of pancreas cancer...
  53. pmc Improved modeling of in vivo kinetics of slowly diffusing radiotracers for tumor imaging
    Moses Q Wilks
    Department of Biomathematics, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine the University of California Los Angeles, Los Angeles, California
    J Nucl Med 55:1539-44. 2014
    ..In this work, we investigate the effects of subvoxel spatial heterogeneity on measured time-activity curves in PET imaging and the effects of ignoring diffusion limitation on parameter estimates from kinetic modeling...
  54. pmc Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7
    Daniel P Widney
    Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 8:e72414. 2013
    ..This mouse model may be useful for future studies on the interactions of the innate immune system and AIDS-BL tumor cells, as well as for the assessment of potential tumor biomarkers for this disease. ..
  55. pmc Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor
    Noah Federman
    Division of Pediatric Hematology Oncology, Department of Pediatrics, Mattel Children s Hospital and Gwynne Hazen Cherry Memorial Laboratories, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095 1781, USA
    Sarcoma 2012:126906. 2012
    ..In this way, α-AL-HPLNs are a promising new strategy to specifically deliver cytotoxic agents in osteosarcoma...
  56. pmc Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT
    Sepideh Afshar
    Department of Microbiology, Immunology, and Molecular Genetics, UCLA, 247 BSRB, 615 Charles E, Young East, Los Angeles, 90095, USA
    J Exp Clin Cancer Res 28:147. 2009
    ..To overcome the problem of immunogenicity, a fully human enzyme, capable of converting a non-toxic prodrug to cytotoxic drug was developed and joined to a human tumor specific scFv yielding a fully human targeting agent...
  57. ncbi request reprint Solution-phase surface modification in intact poly(dimethylsiloxane) microfluidic channels
    Guodong Sui
    Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 700 Westwood Plaza, Los Angeles, California 90095, USA
    Anal Chem 78:5543-51. 2006
    ..The resulting biomolecule-grafted PDMS microchannels can be utilized for cell immobilization and incubation, semiquantitative DNA hybridization, and immunoassay...
  58. ncbi request reprint Engineering multivalent antibody fragments for in vivo targeting
    Anna M Wu
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Methods Mol Biol 248:209-25. 2004
  59. ncbi request reprint A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn)
    Gregory Z Ferl
    Biocybernetics Laboratory, Department of Computer Science, University of California, Los Angeles, CA 90095 1596, USA
    Ann Biomed Eng 33:1640-52. 2005
    ....
  60. pmc An internet-based "kinetic imaging system" (KIS) for MicroPET
    Sung Cheng Huang
    Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, University of California in Los Angeles, CA 90095, USA
    Mol Imaging Biol 7:330-41. 2005
    ..KIS is designed for biology/pharmaceutical scientists to make learning and applying tracer kinetics fun and easy...
  61. pmc The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry
    Kouki Morizono
    Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
    Cell Host Microbe 9:286-98. 2011
    ..These results reveal an alternative molecular mechanism of viral entry that can broaden host range and enhance infectivity of enveloped viruses...
  62. ncbi request reprint Engineering A11 Minibody-Conjugated, Polypeptide-Based Gold Nanoshells for Prostate Stem Cell Antigen (PSCA)-Targeted Photothermal Therapy
    Kristine M Mayle
    Department of Bioengineering, University of California, Los Angeles, CA, USA
    J Lab Autom . 2016
    ..Our experimental and theoretical results demonstrate the potential of our novel minibody-conjugated gold nanoshells for metastatic prostate cancer therapy...
  63. ncbi request reprint Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice
    Pritha Ray
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Gefen School of Medicine, University of California, Los Angeles, California 90095, USA
    Cancer Res 63:1160-5. 2003
    ..Using a single fusion reporter (PET/optical) gene should accelerate the validation of reporter gene approaches developed in cell culture for translation into preclinical and clinical models...
  64. ncbi request reprint Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output
    Andreas Markus Loening
    The Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Protein Eng Des Sel 19:391-400. 2006
    ....
  65. ncbi request reprint A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies
    Jeffrey Y C Wong
    City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA
    Cancer Biother Radiopharm 21:88-100. 2006
    ..The aim of this phase I therapy trial was to evaluate cT84.66 conjugated to the macrocyclic chelate (90)Y-DOTA and labeled with (90)Y in a comparable patient population...
  66. ncbi request reprint A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer
    Jeffrey Y C Wong
    Division of Radiation Oncology, Beckman Research Institute and City of Hope National Medical Center and Beckman Research Institute, Duarte, California 91010, USA
    Clin Cancer Res 9:5842-52. 2003
    ..The primary objective of this trial was to evaluate the feasibility and toxicities of systemic 90Y-chimeric T84.66 (cT84.66) anti-carcinoembryonic antigen RIT in combination with continuous infusion 5-fluorouracil (5-FU)...
  67. ncbi request reprint Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer
    Jeffrey Y C Wong
    Division of Radiation Oncology, City of Hope National Medical Center and Beckman Research Institute, Duarte, California 91010, USA
    Clin Cancer Res 10:5014-21. 2004
    ..66 minibody demonstrated tumor targeting and was well tolerated as well as to begin to evaluate its biodistribution, pharmacokinetics, and immunogenicity in patients with colorectal cancer...
  68. ncbi request reprint Expression of recombinant antibodies in mammalian cell lines
    Paul J Yazaki
    Beckman Research Institute of the City of Hope National Medical Center, Duarte, CA, USA
    Methods Mol Biol 248:255-68. 2004
  69. ncbi request reprint Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody
    Lin Li
    Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA
    Bioconjug Chem 17:68-76. 2006
    ....
  70. ncbi request reprint PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody
    Weibo Cai
    Molecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, California 94305 5484, USA
    J Nucl Med 48:304-10. 2007
    ..66 diabody, a genetically engineered noncovalent dimer of single-chain variable fragments, for small-animal PET imaging of CEA expression in xenograft-bearing mice...
  71. pmc microPET-based biodistribution of quantum dots in living mice
    Meike L Schipper
    Departments of Radiology and Bioengineering, Bio X Program, Molecular Imaging Program at Stanford MIPS, Stanford University, East 150 Clark Center, Palo Alto, CA 94305, USA
    J Nucl Med 48:1511-8. 2007
    ..This study evaluates the quantitative biodistribution of commercially available CdSe quantum dots (QD) in mice...
  72. pmc Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments
    Vania Kenanova
    Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA
    Cancer Res 65:622-31. 2005
    ..Thus, attenuating the Fc-FcRn interaction provides a way of controlling the antibody fragment serum half-life without compromising expression and tumor targeting...
  73. ncbi request reprint Humanization of the anti-CEA T84.66 antibody based on crystal structure data
    Paul J Yazaki
    Department of Radioimmunotherapy, Division of Radiology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Protein Eng Des Sel 17:481-9. 2004
    ..66's ability to support clinical trials. Planned clinical trials will determine the effective utilization of this structure-based approach in the development of a promising new therapeutic...
  74. ncbi request reprint Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy
    Vania Kenanova
    Division of Molecular Biology, Beckman Research Institute of the City of Hope, Department of Radioimmunotherapy, Duarte, CA, USA
    Cancer Res 67:718-26. 2007
    ..Finally, the 125I/111In biodistribution data allowed for dose estimations, which suggest the 131I-labeled scFv-Fc H310A/H435Q as a promising candidate for radioimmunotherapy...
  75. ncbi request reprint The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility
    Jennifer A Carmichael
    CSIRO Health Sciences and Nutrition, 343 Royal Parade, Parkville 3052, Vic, Australia
    J Mol Biol 326:341-51. 2003
    ..This analysis therefore provides some signposts that may impact on future molecular designs for these therapeutic molecules with respect to diabody flexibility and avidity...
  76. ncbi request reprint Red-shifted Renilla reniformis luciferase variants for imaging in living subjects
    Andreas Markus Loening
    Molecular Imaging Program at Stanford, Departments of Radiology and Bioengineering, Bio X Program, Stanford University, Stanford, California 94305, USA
    Nat Methods 4:641-3. 2007
    ..To overcome this, we generated variants of RLuc with bathochromic (red) shifts of up to 66 nm (547 nm peak) that also had greater stability and higher light emission than native RLuc...
  77. ncbi request reprint Construction and characterization of minibodies for imaging and therapy of colorectal carcinomas
    Paul J Yazaki
    Department of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA
    Methods Mol Biol 207:351-64. 2003

Research Grants1

  1. High-avidity multimeric cancer imaging agent
    Anna Wu; Fiscal Year: 2005
    ..abstract_text> ..